NCT03193281 2023-11-29
KISS
University of Auckland, New Zealand
Phase 2 Unknown
Clinical Trials
27 trialsNCT05638763 2022-12-06
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05559008 2022-11-09
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
Phase 1/2 Unknown
NCT03318770 2022-10-12
Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT03173612 2022-08-03
The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT04155411 2022-07-27
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Shenzhen Second People's Hospital
Phase 4 Unknown
NCT03564470 2022-07-01
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT05042531 2022-04-25
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
LanZhou University
Phase NA Unknown
NCT05024357 2021-10-01
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT05026229 2021-10-01
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT04284202 2020-02-25
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
The Affiliated Hospital of Qingdao University
Phase 2 Unknown
NCT02268370 2019-11-29
TRAD
University Health Network, Toronto
Phase 2 Unknown
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02744768 2018-03-22
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT03331211 2017-11-08
Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
Unknown
NCT03216070 2017-07-13
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4 Unknown
NCT01685125 2017-07-07
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Southern California
Phase 2 Unknown
NCT02015728 2016-12-15
SEED
Seattle Children's Hospital
Phase NA Unknown
NCT02776878 2016-05-18
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT01802450 2015-09-17
DASAPOST
PETHEMA Foundation
Phase 2 Unknown
NCT01887561 2013-06-27
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
Kanto CML Study Group
Phase 2 Unknown
NCT01627132 2012-06-25
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Shimousa Hematology Study Group
Phase 2 Unknown
NCT01051115 2011-08-31
D'ACCORD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown
NCT00112775 2011-06-07
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00979160 2009-09-18
Evaluation of Response of Dasatinib to Treat Mastocytosis
Federico II University
Phase 2 Unknown